http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4307b79a61b6adb83cff0822bb9c486d
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Schellens H.M. Schellens HM Schellens |
| name | Jan HM. Schellens Jan H.M. Schellens Jan HM Schellens Jan H.M Schellens |
| given-name | Jan Jan HM. Jan H.M. Jan H.M Jan HM |
| organization-name | The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Slotervaant Hospital, Amsterdam, The Netherlands; Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, Utrecht University, Utrecht, The Netherlands Division of Medical Oncology, Department of Clinical Pharmacology Netherlands Cancer Institute Amsterdam The Netherlands; Department of Molecular Pathology Netherlands Cancer Institute Amsterdam The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Department of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands From the Department of Medical Oncology, University Medical Center Utrecht, Utrecht; Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen; The Netherlands Cancer Institute; Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands; Royal Marsden Hospital, Sutton, Surrey; AstraZeneca, Alderley Park, Macclesfield, United Kingdom; Tumor Biology Center, Albert Ludwigs University; University Hospital; Cancer Hospital Sanafontis, Freiburg; and the... 1Division of Experimental Therapy and; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital;; 4Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Department of Clinical Pharmacology The Netherlands Cancer Institute Amsterdam The Netherlands; Division of Pharmaco‐epidemiology & Clinical Pharmacology Science Faculty Utrecht Institute for Pharmaceutical Sciences Utrecht University Utrecht The Netherlands 1Division of Clinical Pharmacology, Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute;; 4Division of Drug Toxicology, Section of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands; a Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;; c Science Faculty, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Utrecht University, Utrecht, The Netherlands Annelies H. Boekhout, Andrew D. Vincent, Otilia B. Dalesio, Joke H. Foekema-Töns, Sandra Adriaansz, Jos H. Beijnen, and Jan H.M. Schellens, the Netherlands Cancer Institute; Bastiaan Nuijen and Jos H. Beijnen, Slotervaart Hospital, Amsterdam; Joan van den Bosch and Sylvia Sprangers, Albert Schweitzer Hospital, Dordrecht; and Jos H. Beijnen and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands. Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Utrecht, The Netherlands. Division of Clinical Pharmacology Department of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology Faculty of Science Department of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam; Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht University, Utrecht, the Netherlands Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;; Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Science Faculty, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, University of Utrecht, Sorbonnelaan 14–16, 3584 CA Utrecht, The Netherlands Utrecht University, Utrecht, the Netherlands Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands Authors' Affiliations: 1Division of Clinical Pharmacology, Department of Medical Oncology, 2Department of Experimental Therapy, 3Biometrics Department, and 4Division of Gastroenterology and Hepatology, Department of Medical Oncology, The Netherlands Cancer Institute; Departments of 5Molecular Biology and 6Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam; 7Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen; 8Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Pharmacotherapy; 9Faculty of Science, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Utrecht University, Utrecht; and 10Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; Authors' Affiliations: 1Division of Clinical Pharmacology, Department of Medical Oncology, 2Department of Experimental Therapy, 3Biometrics Department, and 4Division of Gastroenterology and Hepatology, Department of Medical Oncology, The Netherlands Cancer Institute; Departments of 5Molecular Biology and 6Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam; 7Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen; 8Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Pharmacotherapy; 9Faculty of Science, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Utrecht University, Utrecht; and 10Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; Authors' Affiliations: 1Division of Clinical Pharmacology, Department of Medical Oncology, 2Department of Experimental Therapy, 3Biometrics Department, and 4Division of Gastroenterology and Hepatology, Department of Medical Oncology, The Netherlands Cancer Institute; Departments of 5Molecular Biology and 6Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam; 7Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen; 8Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Pharmacotherapy; 9Faculty of Science, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Utrecht University, Utrecht; and 10Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands Division of Pharmacology The Netherlands Cancer Institute Amsterdam the Netherlands; Department of Clinical Pharmacology, Division of Medical Oncology The Netherlands Cancer Institute Amsterdam the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences Faculty of Science, Utrecht University Utrecht the Netherlands Department of Clinical Pharmacology The Netherlands Cancer Institute Amsterdam The Netherlands; Faculty of Science Department of Pharmaceutical Sciences Division of Clinical Pharmacology and Pharmacoepidemiology Utrecht University Utrecht The Netherlands Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences Utrecht University Utrecht The Netherlands 2The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands;; 5Utrecht University, Utrecht, the Netherlands From the Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, and Department of Pharmacy and Pharmacology, Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam, the Netherlands; and Rhône-Poulenc Rorer Recherche-Développement, Anthony Cedex, France. Department of Clinical Pharmacology, Division of Medical Oncology and Division of Pharmacology the Netherlands Cancer Institute Amsterdam the Netherlands; Utrecht Institute for Pharmaceutical Sciences Utrecht University Utrecht the Netherlands Division of Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands The Netherlands Cancer Institute, Amsterdam, The Netherlands; Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands Department of Clinical Pharmacology The Netherlands Cancer Institute Amsterdam The Netherlands; Department of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands JHM Schellens: Department of Pharmacy and Pharmacology, Slotervaart Hospital, Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands, and Department of Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands; Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Pharmacoepidemiology & Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands Authors' Affiliations: 1European Medicines Agency, London, United Kingdom; 2Lægemiddelstyrelsen, København, Denmark; 3Agence Française de Sécurité Sanitaire des Produits de Santé, Saint-Denis, France; 4College ter Beoordeling van Geneesmiddelen and 5Medicines Evaluation Board, The Hague; 6Netherlands Cancer Institute, Amsterdam; 7Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Authors' Affiliations: 1European Medicines Agency, London, United Kingdom; 2Lægemiddelstyrelsen, København, Denmark; 3Agence Française de Sécurité Sanitaire des Produits de Santé, Saint-Denis, France; 4College ter Beoordeling van Geneesmiddelen and 5Medicines Evaluation Board, The Hague; 6Netherlands Cancer Institute, Amsterdam; 7Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands From the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, University Utrecht, Utrecht, the Netherlands; Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; and Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ From the Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/the Netherlands Cancer Institute, Amsterdam; the Department of Pharmacy and Pharmacology, Slotervaart Hospital/the Netherlands Cancer Institute, Amsterdam, the Netherlands; and Pharmacia and Upjohn, Oncology Research and Development, Milan, Italy. From the Drug Development Unit, Royal Marsden National Health Service Foundation Trust; The Institute of Cancer Research, Sutton, Surrey; Institute of Genetics and Molecular Medicine, University of Edinburgh Cancer Research, Edinburgh; the Breakthrough Breast Cancer Research Unit at King's College London, Guy's Campus; the Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; the Netherlands Cancer... 1Division of Experimental Therapy,; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,; 5Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; Science Faculty, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Utrecht University, P.O. Box 80082, 3508 TB, Utrecht, The Netherlands Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, 3508 TB Utrecht, The Netherlands 1Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; 9Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Utrecht, the Netherlands. Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht, The Netherlands Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands 1Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; 2Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; 4Modra Pharmaceuticals BV, Amsterdam, the Netherlands.; 5Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands. 1Division of Experimental Therapy and; 2Department of Medical Oncology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital;; 4Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht University; Department of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands 2Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands;; 5Department of Biomedical Analysis, Section of Drug Toxicology, Utrecht University, Utrecht, the Netherlands 2Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands and; 3Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands 1Department of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 4Faculty Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Faculty of Science, Utrecht Institute of Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands Authors' Affiliations: Departments of 1Clinical Chemistry/Preclinical Pharmacology, 2Experimental Therapy & Medical Oncology, 3Molecular Oncology, and 4Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, EC Amsterdam; 5Division of Drug Toxicology, Faculty of Pharmacy; Division of Biomedical Analysis, Faculty of Science, Utrecht University, Utrecht, the Netherlands; and 6Department of Internal Medicine - Section of Medical Oncology, Postgraduate School of Oncology, University of Florence - School of Medicine, Azienda Universitario-Ospedaliera Careggi, Florence, Italy; Authors' Affiliations: Departments of 1Clinical Chemistry/Preclinical Pharmacology, 2Experimental Therapy & Medical Oncology, 3Molecular Oncology, and 4Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, EC Amsterdam; 5Division of Drug Toxicology, Faculty of Pharmacy; Division of Biomedical Analysis, Faculty of Science, Utrecht University, Utrecht, the Netherlands; and 6Department of Internal Medicine - Section of Medical Oncology, Postgraduate School of Oncology, University of Florence - School of Medicine, Azienda Universitario-Ospedaliera Careggi, Florence, Italy Maarten J. Deenen, Didier Meulendijks, Annemieke Cats, Marjolein K. Sechterberger, Henk Boot, Hilde Rosing, Jos H. Beijnen, and Jan H.M. Schellens, Netherlands Cancer Institute; Paul H. Smits and Marcel Soesan, Slotervaart Hospital, Amsterdam; Johan L. Severens, Erasmus University Medical Center, Rotterdam; Caroline M.P.W. Mandigers, Canisius Wilhelmina Hospital, Nijmegen; and Jos H. Beijnen and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands. a Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands;; d Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands 2Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute;; 25Division of Drug Toxicology, Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands From the University of Texas M.D. Anderson Cancer Center, Houston (S.K., V.M.); West Cancer Center and Research Institute, OneOncology, Germantown, TN (A. Grothey); Memorial Sloan Kettering Cancer Center, New York (R.Y., A.K.); University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium (E.V.C., J. Dekervel); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (J. Desai, C.G.); National Cancer Center Hospital East, Kashiwa, Japan (T.Y.); Hammersmith Hospital, Division of Cancer,... a Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands; c Department of Medical Oncology & Experimental Therapy, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands 13Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; 14Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands. Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d’Oncologia, Barcelona; Manuel Hidalgo, START Madrid; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy,... David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue, Matthew T. Chang, Jonathan B. Reichel, Nancy Bouvier, S. Duygu Selcuklu, Tara E. Soumerai, Jean Torrisi, Joseph P. Erinjeri, Michael F. Berger, Sarat Chandarlapaty, David B. Solit, José Baselga, and Barry S. Taylor, Memorial Sloan Kettering Cancer Center; David B. Solit, Weill Cornell Medical College, Cornell University, New York, NY; J. Carl Barrett and Brian Dougherty, AstraZeneca, Waltham, MA; Helen Ambrose, Andrew Foxley, Justin P.O. Lindemann,... Center for Personalized Cancer Treatment, Utrecht, The Netherlands; Medical Oncology and Clinical Pharmacology Antoni van Leeuwenhoek—The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pharmaceutical Sciences, Science Faculty Utrecht University, Utrecht, The Netherlands a Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;; d Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands 3The Netherlands Cancer Institute, Amsterdam, the Netherlands. Laboratory of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands Jan HM Schellens MD PhD, Professor, Department of Medical Oncology, The Netherlands Cancer Institute; Faculty of Pharmacy, Utrecht University 5The Netherlands Cancer Institute, Amsterdam, the Netherlands. Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Drug Toxicology, Section of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands From the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital and Department of Audiology, Academic Medical Center, Amsterdam; and Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, University Utrecht, Utrecht, the Netherlands. 10The Netherlands Cancer Institute, Amsterdam, The Netherlands. Division of Experimental Therapy, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Clinical Pharmacology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht University, Utrecht, The Netherlands Department of Medical Oncology and Clinical Pharmacology The Netherlands Cancer Institute – Antoni van Leeuwenhoek Amsterdam The Netherlands; Department of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands 1Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital;; 3 Division of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science, University of Utrecht, the Netherlands Authors' Affiliations: 1Dana Farber Cancer Institute and 2Massachusetts General Hospital Cancer Center, Boston, Massachusetts; 3Netherlands Cancer Institute, Division of Clinical Pharmacology, Amsterdam, The Netherlands; 4University of Colorado, Denver, Aurora, Colorado; 5University of California Los Angeles, UCLA Medical Center, Los Angeles, California; 6Clinical Pharmacology and Pharmacometrics, Pfizer (China) Research and Development Center, Shanghai, P.R. China; 7Pfizer Oncology, New London, Connecticut; 8Clinical Development and Medical Affairs, Pfizer Oncology, San Diego, California; and 9Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, University Utrecht, Utrecht, the Netherlands; Authors' Affiliations: 1Dana Farber Cancer Institute and 2Massachusetts General Hospital Cancer Center, Boston, Massachusetts; 3Netherlands Cancer Institute, Division of Clinical Pharmacology, Amsterdam, The Netherlands; 4University of Colorado, Denver, Aurora, Colorado; 5University of California Los Angeles, UCLA Medical Center, Los Angeles, California; 6Clinical Pharmacology and Pharmacometrics, Pfizer (China) Research and Development Center, Shanghai, P.R. China; 7Pfizer Oncology, New London, Connecticut; 8Clinical Development and Medical Affairs, Pfizer Oncology, San Diego, California; and 9Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, University Utrecht, Utrecht, the Netherlands 1Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; 2Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; 3Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; 4Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands. Authors' Affiliations: 1The Netherlands Cancer Institute, Amsterdam; 2Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; 3Oxford NIHR Biomedical Research Centre, Department of Oncology, University of Oxford, Churchill Hospital, Oxford, United Kingdom; 4Medical Oncology Department, Institut Curie, Paris; 5Department of Nuclear Medicine/Center for PET/CT, University Hospital and ICO, René Gauducheau Cancer Center, INSERM Unit 892, Nantes, France; 6Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, Essen; 7Roche Diagnostics GmbH, Penzberg, Germany; 8F.Hoffmann-La Roche Ltd., Basel, Switzerland; and 9F.Hoffmann-La Roche Ltd., Nutley, New Jersey; Authors' Affiliations: 1The Netherlands Cancer Institute, Amsterdam; 2Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; 3Oxford NIHR Biomedical Research Centre, Department of Oncology, University of Oxford, Churchill Hospital, Oxford, United Kingdom; 4Medical Oncology Department, Institut Curie, Paris; 5Department of Nuclear Medicine/Center for PET/CT, University Hospital and ICO, René Gauducheau Cancer Center, INSERM Unit 892, Nantes, France; 6Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, Essen; 7Roche Diagnostics GmbH, Penzberg, Germany; 8F.Hoffmann-La Roche Ltd., Basel, Switzerland; and 9F.Hoffmann-La Roche Ltd., Nutley, New Jersey 2Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute;; 5Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, University of Utrecht, Utrecht, the Netherlands; Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht 2Medical Oncology,; 5Division of Drug Toxicology, Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands Authors' Affiliations: 1Division of Clinical Pharmacology, The Netherlands Cancer Institute; 2Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam; 3Department of Medical Oncology, University Medical Center; 4Division of Drug Toxicology, Section of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands; and 5Eli Lilly and Company, Indianapolis, Indiana; Authors' Affiliations: 1Division of Clinical Pharmacology, The Netherlands Cancer Institute; 2Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam; 3Department of Medical Oncology, University Medical Center; 4Division of Drug Toxicology, Section of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands; and 5Eli Lilly and Company, Indianapolis, Indiana; Authors' Affiliations: 1Division of Clinical Pharmacology, The Netherlands Cancer Institute; 2Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam; 3Department of Medical Oncology, University Medical Center; 4Division of Drug Toxicology, Section of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands; and 5Eli Lilly and Company, Indianapolis, Indiana Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands Department of Clinical Chemistry, Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands The Netherlands Cancer Institute, Amsterdam, The Netherlands, and Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht, The Netherlands Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke, Daphne de Jong, Efraim H. Rosenberg, Serena Marchetti, Dick Pluim, Erik van Werkhoven, Jos H. Beijnen, and Jan H.M. Schellens, The Netherlands Cancer Institute, Amsterdam; Jos H. Beijnen and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands; and Shelonitda Rose, Mark A. Lee, and Tomoko Freshwater, Merck, Kenilworth, NJ. From The Netherlands Cancer Institute, 1066 CX Amsterdam, and LAREB, 5237 MH 'sHertogenbosch, the Netherlands. 7Utrecht University, Utrecht, the Netherlands. Division of Pharmacology and Division of Clinical Pharmacology, Department of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands; Utrecht Institute for Pharmaceutical Sciences, Utrecht University Utrecht The Netherlands From the Division of Pharmacology (M.T.J.v.B., D.P., B.M.K., J.H.B., J.H.M.S.), Clinical Pharmacology (M.T.J.v.B., B.M.K., J.H.B., J.H.M.S), Division of Pathology (M.B.), Department of Biometrics (K.S.), Department of Laboratory Medicine (D.T.C.L., D.v.d.B.), and Department of Neuro-oncology (D.B.), Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam; and Science Faculty (J.H.B., J.H.M.S), Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht... a Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; b Division of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research... Department of Clinical Pharmacology, Division of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands; Faculty of Science, Utrecht Institute of Pharmaceutical Sciences (UIPS), Division of Clinical Pharmacology and Pharmaco‐epidemiology Utrecht University Utrecht The Netherlands Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht, The Netherlands; Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands The Netherlands Cancer Institute, Amsterdam, the Netherlands and Utrecht University, Utrecht, the Netherlands Division of Pharmacology Netherlands Cancer Institute Amsterdam The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht The Netherlands; Department of Medical Oncology Netherlands Cancer Institute Amsterdam The Netherlands Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Drug Toxicology, Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands 1Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; 12Utrecht Institute for Pharmaceutical Sciences (UIPS), University Utrecht, Utrecht, the Netherlands. Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands 6The Netherlands Cancer Institute, Amsterdam, the Netherlands. 1The Netherlands Cancer Institute;; 4Faculty of Pharmaceutical Sciences, Utrecht, the Netherlands Netherlands Cancer Institute, Amsterdam; and Utrecht University, Utrecht, the Netherlands Linda M. Henricks, Astrid A.M. van der Veldt, and Jan H.M. Schellens, the Netherlands Cancer Institute; André B.P. van Kuilenburg, Academic Medical Center, Amsterdam; Emma Kienhuis, Femke M. de Man, Astrid A.M. van der Veldt, Ron H.N. van Schaik, and Ron H.J. Mathijssen, Erasmus Medical Center; Paul Hamberg, Franciscus Gasthuis & Vlietland, Rotterdam; Carin A.T.C. Lunenburg and Henk-Jan Guchelaar, Leiden University Medical Center, Leiden; and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands. Suzanne Leijen, Robin M.J.M. van Geel, and Jan H.M. Schellens, The Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands; Anna C. Pavlick, New York University Medical Center, New York, NY; Lee Rosen, University of California Los Angeles, Santa Monica, CA; Raymond Lam, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, and Stuart Shumway, Merck, Kenilworth, NJ; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Albiruni R. Abdul Razak and Amit... Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands 1The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital;; 3Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, University Utrecht, Utrecht, the Netherlands; and 11The Netherlands Cancer Institute, Amsterdam, the Netherlands. Department of Clinical Pharmacology, Division of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands; Division of Molecular Pathology The Netherlands Cancer Institute Amsterdam The Netherlands; Faculty of Science, Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht Institute for Pharmaceutical Sciences, Utrecht University Utrecht The Netherlands Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands The Netherlands Cancer Institute Amsterdam The Netherlands; Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University Utrecht The Netherlands Department of Clinical Pharmacology Netherlands Cancer Institute; Science Faculty, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology Utrecht University Utrecht The Netherlands 4The Netherlands Cancer Institute, Amsterdam, the Netherlands. Department of Clinical Pharmacology; Division of Medical Oncology; The Netherlands Cancer Institute; Amsterdam The Netherlands; Division of Molecular Pathology; The Netherlands Cancer Institute; Amsterdam The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology; Department of Pharmaceutical Sciences; Faculty of Science, Utrecht University; Utrecht The Netherlands Department of Medical Oncology & Clinical Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands From the Departments of Medical Oncology and Gynecology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, the Netherlands; Department of Medical Oncology, Medical Spectrum Twente, Enschede, the Netherlands; and SmithKline Beecham Pharmaceuticals, Harlow, United Kingdom. Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Science Faculty, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Utrecht University, Utrecht, The Netherlands a Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; b Department of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands; e Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht University, Utrecht, The Netherlands Franceso Trotta, Giovanni Tafuri, Italian Medicines Agency, Rome, Italy; Hubert G.M. Leufkens, Jan H.M. Schellens, Giovanni Tafuri, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht; Hubert G.M. Leufkens, Jan H.M. Schellens, Medicines Evaluation Board, The Hague; Jan H.M. Schellens, The Netherlands Cancer Institute, Amsterdam, the Netherlands; and Richard Laing, WHO, Geneva, Switzerland. Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Utrecht, The Netherlands 4Medical Oncology; and; 6Faculty of Pharmaceutical Sciences, University of Utrecht, Utrecht, the Netherlands Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, and Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmaco-epidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands From the Department of Medical Oncology, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Pharmacy and Pharmacology, the Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Utrecht; and Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands. 1Experimental Therapy, Divisions of; 4Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands and; 5Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands 1Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. b Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; c Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht, The Netherlands 6The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, the Netherlands. 1Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute;; 2Department of Clinical Pharmacy, Slotervaart Hospital, Amsterdam, the Netherlands;; 4Faculty of Pharmaceutical Sciences, University Utrecht, Utrecht, the Netherlands; and Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;; Science Faculty, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmaco-epidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands Utrecht University, Faculty of Science, Department of Pharmaceutical, Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht, The Netherlands; The Netherlands Cancer Institute, Department of Medical Oncology, Division of Clinical Pharmacology, Amsterdam, The Netherlands From the University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh; Cancer Research United Kingdom Clinical Trials Unit, Beatson West of Scotland Cancer Centre Level 0, Glasgow; ANCHOR Unit and University of Aberdeen, Aberdeen Royal Infirmary, Foresterhill, Aberdeen; Cancer Medicine Research Programme, Section of Translational Medical Sciences, School of Medicine and Dentistry, University of Aberdeen, Foresterhill, Aberdeen,... 1Experimental Therapy and Medical Oncology and Departments of; 3Science Faculty, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Utrecht University, Utrecht, The Netherlands; and Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for... a Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;; d Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology & Pharmaco-epidemiology and Clinical Pharmacology, Utrecht, The Netherlands 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 1The Netherlands Cancer Institute, Amsterdam, the Netherlands.; 20Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands. 1Division of Clinical Pharmacology, The Netherlands Cancer Institute;; 3Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, University Utrecht, Utrecht, the Netherlands Authors' Affiliations: 1Department of Medical Oncology, University Medical Center Utrecht and 2Science Faculty, Department Pharmaceutical Sciences, Division Drug Toxicology, Utrecht University, Utrecht, the Netherlands; 3Division of Clinical Pharmacology, the Netherlands Cancer Institute Amsterdam, Amsterdam, the Netherlands; and 4Bayer Schering Pharma AG, Wuppertal, Germany; Authors' Affiliations: 1Department of Medical Oncology, University Medical Center Utrecht and 2Science Faculty, Department Pharmaceutical Sciences, Division Drug Toxicology, Utrecht University, Utrecht, the Netherlands; 3Division of Clinical Pharmacology, the Netherlands Cancer Institute Amsterdam, Amsterdam, the Netherlands; and 4Bayer Schering Pharma AG, Wuppertal, Germany Department of Clinical Pharmacology, Division of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands 1Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute;; 5Division of Drug Toxicology, Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands Department of Clinical Pharmacology The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pharmaceutical Sciences Utrecht University, Utrecht, The Netherlands |
Incoming Links
Total number of triples: 459.